1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Left Main Stem Percutaneous Coronary Intervention: Does On-Site Surgical Cover Make a Difference?

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Nonsurgical centers (NSC) contribute significantly to the capacity of overall percutaneous coronary intervention (PCI) in the United Kingdom. Although previous studies have demonstrated similar PCI outcomes in surgical centers (SC) versus NSC, it is unknown whether this applies to more complex procedures such as left main stem (LMS) PCI. We compared patient characteristics and outcomes of LMS PCI performed across SC and NSC in England and Wales.

          Methods:

          A retrospective analysis of procedures between January 2006 and March 2020 was performed using the British Cardiovascular Intervention Society database and stratified according to the surgical status of the center. The primary outcomes assessed were in-hospital major adverse cardiovascular and cerebrovascular events, all-cause mortality, and Bleeding Academic Research Consortium stage 3 to 5 bleeding.

          Results:

          Forty thousand seven hundred forty-four patients underwent LMS PCI during the period, of which 13 922 (34.2%) had their procedure performed at an NSC. The proportion of LMS PCI performed in NSC increased >2-fold (15.9% in 2006 to 36.7% in 2020). There was no association between surgical cover location and in-hospital mortality (odds ratio, 0.92 [95% CI, 0.69–1.22]), in-hospital major adverse cardiovascular and cerebrovascular events (odds ratio, 1.00 [95% CI, 0.79–1.25]), or emergency coronary artery bypass graft surgery (odds ratio, 1.00 [95% CI, 0.95–1.06]). NSC had lower Bleeding Academic Research Consortium 3 to 5 bleeding complications (odds ratio, 0.53 [95% CI, 0.34–0.82]).

          Conclusions:

          There has been an increase in LMS PCI volumes at NSC, particularly elective LMS PCI. LMS PCI performed at NSC was not associated with increased mortality, in-hospital major adverse cardiovascular and cerebrovascular events, or emergency coronary artery bypass graft surgery, despite higher disease complexity.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: not found
          • Article: not found

          2018 ESC/EACTS Guidelines on myocardial revascularization

            Bookmark
            • Record: found
            • Abstract: not found
            • Book: not found

            Multiple Imputation for Nonresponse in Surveys

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

              Small trials have suggested that radial access for percutaneous coronary intervention (PCI) reduces vascular complications and bleeding compared with femoral access. We aimed to assess whether radial access was superior to femoral access in patients with acute coronary syndromes (ACS) who were undergoing coronary angiography with possible intervention. The RadIal Vs femorAL access for coronary intervention (RIVAL) trial was a randomised, parallel group, multicentre trial. Patients with ACS were randomly assigned (1:1) by a 24 h computerised central automated voice response system to radial or femoral artery access. The primary outcome was a composite of death, myocardial infarction, stroke, or non-coronary artery bypass graft (non-CABG)-related major bleeding at 30 days. Key secondary outcomes were death, myocardial infarction, or stroke; and non-CABG-related major bleeding at 30 days. A masked central committee adjudicated the primary outcome, components of the primary outcome, and stent thrombosis. All other outcomes were as reported by the investigators. Patients and investigators were not masked to treatment allocation. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, NCT01014273. Between June 6, 2006, and Nov 3, 2010, 7021 patients were enrolled from 158 hospitals in 32 countries. 3507 patients were randomly assigned to radial access and 3514 to femoral access. The primary outcome occurred in 128 (3·7%) of 3507 patients in the radial access group compared with 139 (4·0%) of 3514 in the femoral access group (hazard ratio [HR] 0·92, 95% CI 0·72-1·17; p=0·50). Of the six prespecified subgroups, there was a significant interaction for the primary outcome with benefit for radial access in highest tertile volume radial centres (HR 0·49, 95% CI 0·28-0·87; p=0·015) and in patients with ST-segment elevation myocardial infarction (0·60, 0·38-0·94; p=0·026). The rate of death, myocardial infarction, or stroke at 30 days was 112 (3·2%) of 3507 patients in the radial group compared with 114 (3·2%) of 3514 in the femoral group (HR 0·98, 95% CI 0·76-1·28; p=0·90). The rate of non-CABG-related major bleeding at 30 days was 24 (0·7%) of 3507 patients in the radial group compared with 33 (0·9%) of 3514 patients in the femoral group (HR 0·73, 95% CI 0·43-1·23; p=0·23). At 30 days, 42 of 3507 patients in the radial group had large haematoma compared with 106 of 3514 in the femoral group (HR 0·40, 95% CI 0·28-0·57; p<0·0001). Pseudoaneurysm needing closure occurred in seven of 3507 patients in the radial group compared with 23 of 3514 in the femoral group (HR 0·30, 95% CI 0·13-0·71; p=0·006). Radial and femoral approaches are both safe and effective for PCI. However, the lower rate of local vascular complications may be a reason to use the radial approach. Sanofi-Aventis, Population Health Research Institute, and Canadian Network for Trials Internationally (CANNeCTIN), an initiative of the Canadian Institutes of Health Research. Copyright © 2011 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Circulation: Cardiovascular Interventions
                Circ: Cardiovascular Interventions
                Ovid Technologies (Wolters Kluwer Health)
                1941-7640
                1941-7632
                October 2022
                October 2022
                : 15
                : 10
                Affiliations
                [1 ]Keele Cardiovascular Research Group, School of Medicine, Keele University, Stoke-on-Trent, United Kingdom (M.R., S.M., M.A.M.).
                [2 ]Department of Academic Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom (M.R., S.M., M.A.M.).
                [3 ]Department of Cardiology, Manchester Foundation Trust, Manchester, United Kingdom (M.Z.).
                [4 ]Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (P.L.).
                [5 ]Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (H.C.W.).
                [6 ]Faculty of Medicine, University of Southampton &amp; Department of Cardiology, University Hospital of Southampton, United Kingdom (N.C.).
                [7 ]Department of Cardiology, University Hospital of Wales, Cardiff, United Kingdom (T.K.).
                [8 ]Lifespan Cardiovascular Institute, Warren Alpert Medical School at Brown University, Providence, RI (J.D.A.).
                [9 ]Department of Cardiology, Northside Hospital Cardiovascular Institute, Atlanta, GA (C.L.G.).
                Article
                10.1161/CIRCINTERVENTIONS.122.012037
                36256699
                8f09d719-e015-4a03-8ef1-a39b50d70419
                © 2022
                History

                Comments

                Comment on this article